The management of chronic myelogenous leukemia (CML) has undergone profound evolution over a relatively short period of time. Since its identification, the BCR-ABL1 oncoprotein, a hallmark of CML cells, has become the primary molecular target for the development of selective therapeutics for patients with CML.\textsuperscript{1} On 28 May 2001, \textit{TIME} magazine proudly proclaimed “there is new ammunition in the war against cancer—revolutionary new pills like Gleevec combat cancer by targeting only the disease cells.”\textsuperscript{2} Gleevec, the first tyrosine kinase inhibitor (TKI) selectively targeting BCR-ABL1, remarkably altered treatment paradigms and, compared to former nonselective chemotherapy regimens, contributed dramatically to substantially prolonged survival times and improved quality of life for patients with CML.\textsuperscript{3,7} However, 17 years of clinical experience with TKIs has demonstrated that, despite their apparent therapeutic benefit, these drugs are not entirely selective for CML cells, neither are they sufficiently specific for BCR-ABL1. Lack of selectivity, various off-target effects, hematological and nonhematological toxicity, and treatment-induced drug resistance are recurrent and persistent shortcomings of treatment with TKIs that often result in insufficient or unsustainable treatment. Therefore, intense research efforts have focused on development of improved TKIs and alternative treatment strategies to eradicate CML SCs. Alongside efforts to design superior protein inhibitors, the need to overcome the poor therapeutic effect of TKIs on CML SCs has led to a renaissance of antisense strategies, as they are reported as effective in more primitive cell types. Despite the greater drug design flexibility offered by antisense sequence variability and remarkable chemical improvements, antisense drugs exhibit unacceptable levels of off-target effects, precluding them from large-scale clinical testing. Recent advances in antisense drug design have led to a pioneering mRNA recognition concept that may offer a helping hand in eliminating off-target effects, and has potential to bridge the gap between research and clinical practice.

## Keywords
antisense therapy, BCR-ABL1, chronic myelogenous leukemia, selective interaction, target recognition

## Abstract
Chronic myelogenous leukemia (CML) is commonly treated with tyrosine kinase inhibitors (TKIs) that inhibit the pro-leukemic activity of the BCR-ABL1 oncoprotein. Despite the therapeutic progress mediated by TKI use, off-target effects, treatment-induced drug resistance, and the limited effect of these drugs on CML stem cells (SCs) are major drawbacks frequently resulting in insufficient or unsustainable treatment. Therefore, intense research efforts have focused on development of improved TKIs and alternative treatment strategies to eradicate CML SCs. Alongside efforts to design superior protein inhibitors, the need to overcome the poor therapeutic effect of TKIs on CML SCs has led to a renaissance of antisense strategies, as they are reported as effective in more primitive cell types. Despite the greater drug design flexibility offered by antisense sequence variability and remarkable chemical improvements, antisense drugs exhibit unacceptable levels of off-target effects, precluding them from large-scale clinical testing. Recent advances in antisense drug design have led to a pioneering mRNA recognition concept that may offer a helping hand in eliminating off-target effects, and has potential to bridge the gap between research and clinical practice.
drugs indefinitely, and rarely achieve complete recovery. Nevertheless, there are suggestions that a permanent cure can be induced by TKIs, based on results of TKI stop studies, which reported that, after deliberate TKI cessation in a strictly clinically defined cohort of patients with CML, half remained free from disease relapse after 2 years of follow-up. Importantly, because of the restricted detection limit of current methods for monitoring minimal residual disease, it is extremely difficult to discriminate clearly between latent CML and complete cure from the disease. The pitfalls described above highlight the scope for improvement and suggest room for curative treatment approaches with a primary focus on CML SCs and on causal genetic aberrations that trigger leukemogenesis.

A completely different treatment approach is offered by antisense strategies that enable control of disease-associated genes through interaction with mRNA. In theory, any disease associated with a well-defined genetic aberration is amenable to mRNA intervention, and antisense systems allowing specific suppression of BCR-ABL1 mRNA rapidly became a potential treatment alternative for patients with CML. Compared to the limited, structure-based design of protein inhibitors, antisense strategies take advantage of far greater target sequence variability for the design of specific antisense drugs. The benefits of sequence-mediated specificity, allowing selective therapeutic intervention in CML cells, are so great that antisense strategies may be considered one of the most promising future pharmacological prospects for CML treatment since the approval of TKIs.

Interestingly, despite the evident therapeutic potential of antisense strategies, only a minimal number of antileukemic drugs exploiting mRNA interference have reached clinical trials. Biodegradation, limited ability to penetrate cell membranes, and numerous off-target effects are major obstacles hindering the introduction of antisense therapeutics into clinical practice. The difficulties stemming from biodegradation and insufficient cell membrane penetration have been successfully approached using a variety of nucleotide chemical derivatives. By contrast, the issue of unwanted interactions with off-target mRNAs remains a key unresolved obstacle to smooth clinical translation of this therapeutic concept.

Antisense systems for BCR-ABL1 suppression developed to date, 2 of which have even been tested in clinical trials, are based on single antisense oligonucleotides binding to their complementary mRNA sequence spanning the BCR-ABL1 gene fusion junction. Despite successful silencing of BCR-ABL1, in the vast majority of studies, binding to off-target mRNAs resulted in nonselective effects also in BCR-ABL1-negative cells. Interference with nontargeted homologous mRNAs, and consequent suppression of proteins outside of therapeutic intent, is a source of clinically relevant side effects and adverse events. Hence, addressing the issue of insufficient selectivity could significantly accelerate the entry of antisense strategies into clinical practice, and innovative solutions for elimination of this phenomenon are in high demand. A promising target recognition concept was recently reported with the intention of addressing this fundamental problem, and, if proven successful, it could

---

**FIGURE 1** Illustration of the antisense construct and its binding to various mRNAs. A, Partial binding of the antisense construct to an inadvertent mRNA due to the absence of one of the target sequences; B, Partial binding of the antisense construct to an inadvertent mRNA due to the inappropriate distance of target sequences; C, No recognition of the target sequences due to their inappropriate orientation; D, Full recognition of both target sequences and stable binding of the antisense construct to the target BCR-ABL1 mRNA. (A-C) Represent unstable binding modes of the antisense construct and are expected to have a negligible effect on mRNA suppression. (D) Represents the thermodynamically and energetically preferred binding mode of the antisense construct leading to selective suppression of target mRNA. CD26 cell surface marker allows for direct targeting of CML SCs.
substantially reduce, or even eliminate, undesired off-target effects. In the context of CML, the concept may facilitate specific BCR-ABL1 mRNA recognition, and hence selective therapeutic intervention, exclusively in CML cells.

The solution addresses the basic design of the antisense construct, which is engineered to recognize the target mRNA via 2 antisense oligonucleotides connected by a size-specific linker (Figure 1). Simultaneous sequence-specific binding of individual antisense oligonucleotides to complementary sequences of partner BCR and ABL1 mRNAs flanking the gene fusion junction can occur only when these sequences are separated from one another by a specific distance, which is defined by the linker. This simple but strict requirement significantly reduces the probability of stable interference with off-target mRNAs, and thereby may provide dramatically enhanced selectivity towards CML cells.

This selective antisense strategy is based on the assumption that partial interaction of the antisense construct with wild-type BCR and ABL1 gene sequences, or with homologous sequences of off-target mRNAs, will be thermodynamically unstable and energetically unfavorable because of the increased degree of conformational freedom and the absence of cooperative hydrogen bonds, respectively (Figure 1A-C). Furthermore, any stable intermolecular interactions between the antisense construct and partially complementary mRNAs are even more improbable. Such nonspecific interactions are therefore expected to have negligible effects on the suppression of nontarget mRNAs. Consequently, selective interference with BCR-ABL1 mRNA (Figure 1D) will ensure therapeutic intervention only in CML cells, substantially reducing the potential for side effects and adverse events. Moreover, as antisense systems are reported to function, not only in actively proliferating cells, but also in more primitive CML cells, there is also a real prospect of suppression of BCR-ABL1 mRNA in CML SCs. The hope for a permanent cure for CML has been further advanced by recent reports of the phenotype of CML SCs. The synergy of selective therapeutic intervention and active targeting could facilitate disease eradication with minimal off-target effects. It is important to note, however, that eradication of CML SCs may not be trivial or straightforward, since studies on these cells indicate the presence of complex BCR-ABL1-independent signaling pathways which can contribute to escape from drug-induced apoptosis. Several parallel targets, such as FOXO, BCL6, and CXCR4, or proteins involved in the WNT, Hedgehog and JAK signaling pathways have already been identified as relevant in this respect. In line with the multiple targeting approaches emerging in modern drug R&D, simultaneous selective blocking of the most relevant players may thus represent the future strategy in more effective fight against CML SCs.

The vision of CML SCs eradication got even more realistic contours after the cell surface marker CD26 has been identified as discriminatory from healthy hematopoietic SCs. However, the CD26 surface marker is not specific only to CML SCs, but is expressed also by other, nonhematopoietic cell types. This has obviously led to an objective lag in testing anti-CD26 therapies. Noteworthy though, in case of a drug with exquisite selectivity toward the intracellular target, its overconcentration in the vicinity of a specific cell population via active targeting allows to focus the therapeutic intervention in CD26+ SCs, without undesired effect in CD26+ cells absenting the intracellular target. Comprehensive follow-up research is understandably needed to support this presumption.

Considering the history and evolution of treatment strategies for CML, and irrespective of the tortuous path toward treating CML without side effects, the therapeutic potential of the novel mRNA targeting approach described above is clearly worthy of thorough investigation. The progressive nature of this antisense concept is underlined by its theoretical applicability to any disease where the presence of a particular protein has causal role in pathophysiology. This concept may thus serve as a universal platform for the future design of antisense therapeutics.

The extent to which this novel strategy will be able to alter the status quo in oligonucleotide-based therapeutics will emerge over time. The fascinating possibility of leukemia treatment using a specific agent that can completely spare healthy cells remains a potent stimulus to the continued exploration of this approach and would facilitate its implementation into clinical practice.

ACKNOWLEDGMENTS

This work was supported by the Slovak Research and Development Agency under Contract No. APVV-15-0215 and by VEGA Grant No. 2/0094/15. Rázga F. is receiving support within the SASPRO Programme (Project No. 0057/01/02) co-funded by the European Union and the Slovak Academy of Sciences.

CONFLICT OF INTEREST

The authors declare no potential conflicts of interest.

ORCID

Filip Rázga http://orcid.org/0000-0002-5352-3193

REFERENCES

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.
2. TIME magazine cover. Drugs that fight cancer. TIME. 2001. http://content.time.com/time/covers/0,16641,20010528,00.html
3. Druker BJ, Talpaz M, Dj Resta, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med*. 2001;344:1031-1037.

4. Hehlmann R. CML—Where do we stand in 2015? *Ann Hematol*. 2015;94(Suppl 2):S103-S105.

5. Alldredge BK, Corelli RL, Ernst ME, et al. Applied therapeutics: the clinical use of drugs. In: Koda Kimble M, Youngs LY, eds. *Applied Therapeutics*, 10th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2012.

6. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. *Cancer Pharm Des*. 2010;16:3-10.

7. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. *N Engl J Med*. 2017;376:917-927.

8. Rea D. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. *Ann Hematol*. 2015;94(Suppl 2):S149-S158.

9. Racil Z, Razga F, Drapalova J, et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. *Haematologica*. 2013;98:e124-e126.

10. Razga F, Jurcek T, Zackova D, et al. Role of treatment in the appearance and selection of BCR-ABL kinase domain mutations. *Mol Diagn Ther*. 2012;16:251-259.

11. Cornelison M, Jabbour EJ, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. *J Support Oncol*. 2012;10:14-24.

12. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors – a review on pharmacology, metabolism and side effects. *Curr Drug Metab*. 2009;10:470-481.

13. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukemia. *Lancet Oncol*. 2007;8:1018-1029.

14. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. *J Clin Invest*. 2007;117:2562-2569.

15. Hamilton A, Helgason GV, Schemioneck M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. *Blood*. 2012;119:1501-1510.

16. Zhou H, Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. *Protein Cell*. 2015;6:403-412.

17. Pellicano F, Mukherjee L, Holyoake TL. Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting. *Stem Cells*. 2014;32:1373-1379.

18. Hamad A, Sahli Z, El Sabbah M, Mouteirik M, Nasr R. Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. *Stem Cells Int*. 2013;2013:724360.

19. Preuner S, Mitterbauer G, Mannhalter C, et al. Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone evolution, -expansion, and -depletion in chronic myeloid leukemia. *Eur J Cancer*. 2012;48:233-236.

20. Jørgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equiportant antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. *Blood*. 2007;109:4016-4019.

21. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. *Blood*. 2006;107:4532-4539.

22. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. *Nature*. 2005;435:1267-1270.

23. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. *Blood*. 2003;101:4701-4707.

24. Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. *Blood*. 2002;99:319-325.

25. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic stem cells in chronic myeloid leukemia. *Blood*. 1999;94:2056-2064.

26. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. *Leukemia*. 2007;21:926-935.

27. Saullele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. *Leukemia*. 2016;30:1638-1647.

28. Burnett JC, Rossi JJ. RNA-based therapeutics – current progress and future prospects. *Chem Biol*. 2012;19:60-71.

29. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. *Biotechnol J*. 2011;6:1130-1146.

30. Singh J, Kaur H, Kaushik A, Peer S. A review of antisense therapeutic interventions for molecular biological targets in various diseases. *Int J Pharm*. 2011;7:294-315.

31. Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics. *Silence*. 2010;1:14.

32. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. *Mol Cancer Ther*. 2002;1:347-355.

33. Clinical Trials. https://clinicaltrials.gov/ct2/results?term=RNAi&Search=Search.

34. Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. *Adv Drug Deliv Rev*. 2015;87:46-51.

35. Wickstrom E. DNA and RNA derivatives to optimize distribution from theory to clinical practice. *Adv Drug Deliv Rev*. 2003;99:55-77.

36. Pirollo KF, Rait A, Sleer LS, Chang EH. Antisense therapeutics: a challenge against off-target effects. *Deliv Rev*. 2015;87:25-34.

37. Razga F, Nemethova V. Selective therapeutic intervention: a challenge against off-target effects. *Antisense Therapeutics for Molecular Biological Targets in Various Diseases*. *Int J Pharm*. 2011;7:294-315.

38. Koldehoff M, Steckel NK, Beelen DW, Elmaagachi AH. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. *Clin Exp Med*. 2007;7:47-55.

39. de Fabritiis P, Petti MC, Montefusco E, et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. *Blood*. 1998;91:3156-3162.

40. Haririan M, Kaviani S, Soleimani M, Ghaemi SR, Delalat B, Atashi A. Morpholinol Oligo Antisense efficiently suppresses BCR-ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholinol Oligo Antisense in BCR-ABL6 cells. *Hematology*. 2012;17:28-34.

41. Rapozzi V, Cogoi S, Xodo LE. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells. *Mol Cancer Ther*. 2006;5:1683-1692.
42. Scherr M, Battmer K, Schultheis B, Ganser A, Eder M. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. Gene Ther. 2005;12:12-21.

43. Clark ER. Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia. 2000;14:347-355.

44. Rázga F, Némethová V. A method for altering the functional state of mRNA allowing its selective and specific recognition. WO 2017/065696 A2.

45. Whitey JM, Marley SB, Kaeda J, Harvey AJ, Crompton MR, Gordon MY. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. Br J Haematol. 2005;129:377-380.

46. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood. 2003;101:1566-1569.

47. Herrmann H, Sadovnik I, Cerny-Reiterer S, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014;123:3951-3962.

48. Valent P, Sadovnik I, Racil Z, et al. DPP IV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. Eur J Clin Invest. 2014;44:1239-1245.

49. Cule M, Borsky M, Nemethova V, et al. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukaemia: patient-subgroups, prognostic impact, and technical aspects. Oncotarget. 2016;7:33016-33024.

50. Schulenburg A, Blatt K, Cerny-Reiterer S, et al. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol. 2015;8:16.

51. Scott MT, McCaig AM, Holyoake TL. Hematology education-the program for the annual congress of the European Hematology Association. 16th Congress of the European Hematology Association; June 9-12, 2011; London, United Kingdom, 2011:112-119.

How to cite this article: Némethová V, Rázga F. Chronic myelogenous leukemia on target. Cancer Med. 2018;7:3406-3410. https://doi.org/10.1002/cam4.1604